Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{9a742a38aa314bdbb42b2958771842c1,
title = "Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments",
abstract = "Background: Risk assessment strategies, such as using the American Society of Anesthesiologists (ASA) physical status classification, attempt to identify surgical high-risk patients. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker reflecting overall systemic inflammation and immune activation, and it could potentially improve the identification of high-risk surgical patients. Methods: We included patients acutely admitted to the emergency department who subsequently underwent surgery within 90 days of admission. Patients were stratified into low-risk or high-risk groups, according to ASA classification (ASA low: ASA I–II; ASA high: ASA III–VI) and suPAR level, measured at admission (suPAR high above and suPAR low below 5.5 ng/ml), respectively. Pre-specified complications were identified in national registries and electronic medical records. The association between ASA classification, suPAR level, CRP and the rate of postoperative complications was analyzed with logistic regression and Cox regression analyses, estimating odds ratios and hazard ratios (HRs). Results: During 90-day follow-up from surgery, 31 (7.0{\%}) patients died and 158 (35.6{\%}) patients had postoperative complications. After adjusting for age, sex, and ASA classification, the HR for 90-day postoperative mortality was 2.5 (95{\%} CI 1.6–4.0) for every doubling of suPAR level. suPAR was significantly better than CRP at predicting mortality and all complications (P = 0.0036 and P = 0.0041, respectively). Combining ASA classification and suPAR level significantly improved prediction of mortality and the occurrence of a postoperative complication within 90 days after surgery (P < 0.0001). Conclusion: Measuring suPAR levels in acutely admitted patients may aid in identifying high-risk patients and improve prediction of postoperative complications.",
keywords = "Adult, Aged, Aged, 80 and over, Biomarkers/blood, C-Reactive Protein/metabolism, Female, Health Status, Humans, Male, Middle Aged, Mortality, Postoperative Complications/epidemiology, Predictive Value of Tests, Preoperative Period, Proportional Hazards Models, Receptors, Urokinase Plasminogen Activator/blood, Risk Assessment, Surgical Procedures, Operative",
author = "Morten Alstrup and Jeppe Meyer and Martin Schultz and Rasmussen, {Line Jee Hartmann} and Rasmussen, {Lars Simon} and Lars K{\o}ber and Forberg, {Jakob Lundager} and Jesper Eugen-Olsen and Kasper Iversen",
year = "2019",
month = "3",
doi = "10.1007/s00268-018-4841-1",
language = "English",
volume = "43",
pages = "780--790",
journal = "World Journal of Surgery",
issn = "0364-2313",
publisher = "Springer New York LLC",
number = "3",

}

RIS

TY - JOUR

T1 - Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments

AU - Alstrup, Morten

AU - Meyer, Jeppe

AU - Schultz, Martin

AU - Rasmussen, Line Jee Hartmann

AU - Rasmussen, Lars Simon

AU - Køber, Lars

AU - Forberg, Jakob Lundager

AU - Eugen-Olsen, Jesper

AU - Iversen, Kasper

PY - 2019/3

Y1 - 2019/3

N2 - Background: Risk assessment strategies, such as using the American Society of Anesthesiologists (ASA) physical status classification, attempt to identify surgical high-risk patients. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker reflecting overall systemic inflammation and immune activation, and it could potentially improve the identification of high-risk surgical patients. Methods: We included patients acutely admitted to the emergency department who subsequently underwent surgery within 90 days of admission. Patients were stratified into low-risk or high-risk groups, according to ASA classification (ASA low: ASA I–II; ASA high: ASA III–VI) and suPAR level, measured at admission (suPAR high above and suPAR low below 5.5 ng/ml), respectively. Pre-specified complications were identified in national registries and electronic medical records. The association between ASA classification, suPAR level, CRP and the rate of postoperative complications was analyzed with logistic regression and Cox regression analyses, estimating odds ratios and hazard ratios (HRs). Results: During 90-day follow-up from surgery, 31 (7.0%) patients died and 158 (35.6%) patients had postoperative complications. After adjusting for age, sex, and ASA classification, the HR for 90-day postoperative mortality was 2.5 (95% CI 1.6–4.0) for every doubling of suPAR level. suPAR was significantly better than CRP at predicting mortality and all complications (P = 0.0036 and P = 0.0041, respectively). Combining ASA classification and suPAR level significantly improved prediction of mortality and the occurrence of a postoperative complication within 90 days after surgery (P < 0.0001). Conclusion: Measuring suPAR levels in acutely admitted patients may aid in identifying high-risk patients and improve prediction of postoperative complications.

AB - Background: Risk assessment strategies, such as using the American Society of Anesthesiologists (ASA) physical status classification, attempt to identify surgical high-risk patients. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker reflecting overall systemic inflammation and immune activation, and it could potentially improve the identification of high-risk surgical patients. Methods: We included patients acutely admitted to the emergency department who subsequently underwent surgery within 90 days of admission. Patients were stratified into low-risk or high-risk groups, according to ASA classification (ASA low: ASA I–II; ASA high: ASA III–VI) and suPAR level, measured at admission (suPAR high above and suPAR low below 5.5 ng/ml), respectively. Pre-specified complications were identified in national registries and electronic medical records. The association between ASA classification, suPAR level, CRP and the rate of postoperative complications was analyzed with logistic regression and Cox regression analyses, estimating odds ratios and hazard ratios (HRs). Results: During 90-day follow-up from surgery, 31 (7.0%) patients died and 158 (35.6%) patients had postoperative complications. After adjusting for age, sex, and ASA classification, the HR for 90-day postoperative mortality was 2.5 (95% CI 1.6–4.0) for every doubling of suPAR level. suPAR was significantly better than CRP at predicting mortality and all complications (P = 0.0036 and P = 0.0041, respectively). Combining ASA classification and suPAR level significantly improved prediction of mortality and the occurrence of a postoperative complication within 90 days after surgery (P < 0.0001). Conclusion: Measuring suPAR levels in acutely admitted patients may aid in identifying high-risk patients and improve prediction of postoperative complications.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Biomarkers/blood

KW - C-Reactive Protein/metabolism

KW - Female

KW - Health Status

KW - Humans

KW - Male

KW - Middle Aged

KW - Mortality

KW - Postoperative Complications/epidemiology

KW - Predictive Value of Tests

KW - Preoperative Period

KW - Proportional Hazards Models

KW - Receptors, Urokinase Plasminogen Activator/blood

KW - Risk Assessment

KW - Surgical Procedures, Operative

UR - http://www.scopus.com/inward/record.url?scp=85055982902&partnerID=8YFLogxK

U2 - 10.1007/s00268-018-4841-1

DO - 10.1007/s00268-018-4841-1

M3 - Journal article

VL - 43

SP - 780

EP - 790

JO - World Journal of Surgery

JF - World Journal of Surgery

SN - 0364-2313

IS - 3

ER -

ID: 55573462